Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Language
Publication year range
1.
Endocrinol Diabetes Nutr (Engl Ed) ; 70(3): 212-219, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36967328

ABSTRACT

INTRODUCTION: There are data capture devices that attach to the FreeStyle Libre sensor and convert its communication from NFC (Near-field communication) to Bluetooth technology, generating real-time continuous glucose monitoring. The accuracy of hypoglycemia measurements displayed by smartphone apps using this device has not been established. METHODS: Study of diagnostic tests. Numerical accuracy was evaluated, utilizing the absolute difference with respect to capillary glucometry (ISO 15197:2015 standard) and clinical accuracy, using the Clarke and Parkes (Consensus) error grids, for glucose measurements less than 70mg/dL performed with the FreeStyle Libre system and with the digital estimation xDrip+ app, in diabetic patients managed with insulin therapy. RESULTS: Twenty-seven patients were included (TIR 73.4%, TBR70 5.6%), who contributed 83 hypoglycemic events. Numerical accuracy was adequate in similar proportions with the FreeStyle Libre system compared to the xDrip+ app (81.92% vs. 68.67%, p=0.0630). The clinical accuracy evaluation showed that 92.8% of the measurements for xDrip+ and 98.8% for FreeStyle libre met the criteria according to the Parkes (Consensus) grid (p=0.0535); and 79.5% and 91.6% of the measurements met the criteria according to the Clarke grid (p=0.0273), being higher with FreeStyle libre. CONCLUSIONS: The use of the NFC-Bluetooth transmitter (Miao-Miao) associated with the xDrip+ app does not improve numerical or clinical accuracy for detecting hypoglycemic events in diabetic patients managed with insulin therapy, compared to the FreeStyle Libre device.


Subject(s)
Diabetes Mellitus, Type 1 , Hypoglycemia , Humans , Insulin , Blood Glucose Self-Monitoring , Blood Glucose , Diabetes Mellitus, Type 1/drug therapy , Hypoglycemia/chemically induced , Hypoglycemic Agents/adverse effects
2.
Acta méd. colomb ; 47(2): 32-34, Apr.-June 2022. graf
Article in English | LILACS-Express | LILACS | ID: biblio-1419921

ABSTRACT

Abstract Thyroid cancer is the most common endocrine cancer. It generally has a good prognosis, with a 10-year survival rate of over 90%. Pleural metastasis is uncommon. We present two cases of papillary thyroid cancer with pleural metastases. (Acta Med Colomb 2022; 47. DOI:https://doi.org/10.36104/amc.2022.2216).


Resumen El cáncer de tiroides es la neoplasia endocrinológica más común. Suele presentar un buen pro nóstico con una sobrevida a 10 años mayor al 90%. El compromiso metastásico pleural es poco frecuente. Presentamos dos casos de cáncer papilar de tiroides con compromiso pleural metastásico. (Acta Med Colomb 2022; 47. DOI:https://doi.org/10.36104/amc.2022.2216).

SELECTION OF CITATIONS
SEARCH DETAIL
...